Trial Information

Summary: Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer

A new combination of chemotherapeutic agents to evaluate effectiveness in increasing survival time of patients.

Patient Inclusion Criteria
Cancer of the lung that has spread to other parts of the body.

Patient Exclusion Criteria
No prior treatment for Metastatic lung cancer.

For more information,

Contact:

Kelly Beauchamp, Clinical Research Coordinator
Gainesville Hematology/Oncology Associates
1147 N.W. 64th Terrace
Gainesville, FL 32605
Telephone: 352-264-2543
Fax: 352-331-3802
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:46:22 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA